Affiliation: Queen Mary
- Management of chronic hepatitis C--time for a change?Graham R Foster
Imperial College Faculty of Medicine at St Mary s, St Mary s Hospital, Praed Street, London W2 1PG, UK
J Viral Hepat 9:82-3. 2002
- Review article: pegylated interferons: chemical and clinical differencesG R Foster
Hepatobiliary Group, Adult and Pediatric Gastroenterology, Institute of Molecular and Cellular Science, Queen Mary s School of Medicine and Dentistry, Barts and The Royal London Hospital, London, UK
Aliment Pharmacol Ther 20:825-30. 2004....
- Type I interferons and the innate immune response--more than just antiviral cytokinesPeter L Smith
Hepatobiliary Group, Centre for Adult and Paediatric Gastroenterology, Institute of Cell and Molecular Science, Queen Mary s School of Medicine and Dentistry, Barts and The London, UK
Mol Immunol 42:869-77. 2005....
- Quality of life considerations for patients with chronic hepatitis CG R Foster
The Liver Unit, Clinical Academic Unit of Digestive Diseases, Barts and the London School of Medicine and Dentistry, Queen Marys University of London, London, UK
J Viral Hepat 16:605-11. 2009..Novel agents, with improved adverse effect profiles, may afford more patients the opportunity to achieve a sustained viral response...
- Sustained virologic response rates with telaprevir by response after 4weeks of lead-in therapy in patients with prior treatment failureGraham R Foster
Queen Marys University of London, Institute of Cell and Molecular Science, London, UK Electronic address
J Hepatol 58:488-94. 2013....
- Triple combination treatment for chronic hepatitis C with protease inhibitors, pegylated interferon and ribavirin: 'lead-in or no lead-in'?Graham R Foster
Department of Hepatology, Queen Mary, University of London, London, UK
Liver Int 32:61-3. 2012..Those opposed to the 'lead-in' phase cite the complexity of the regime and the lack of robust evidence showing an improvement in clinical outcome in those treated in this fashion...
- Past, present, and future hepatitis C treatmentsGraham R Foster
Hepatobiliary Group, Department of Adult and Paediatric Gastroenterology, Queen Marys School of Medicine and Dentistry, London, United Kingdom
Semin Liver Dis 24:97-104. 2004....
- Apoptotic cell death: the caspase-cleavage "gold rush"G R Foster
Queen Mary's School of Medicine and Dentistry, Barts and The London NHS Trust, London E1 2AT, UK
Lancet 365:1293-4. 2005
- Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirinGraham R Foster
The Royal London Hospital, London, UK
Scand J Gastroenterol 42:247-55. 2007..The purpose of this study was to model the probability of achieving a sustained virological response in individual patients, taking into consideration various predictive factors...
- Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virusGraham R Foster
Department of Adult and Paediatric Gastroenterology, The Royal London Hospital, Turner Street, London, E1 2AD, UK
Expert Opin Pharmacother 4:685-91. 2003..Their ease of administration, coupled with their improved efficacy, is likely to lead to an increase in the proportion of infected patients who wish to receive treatment...
- Hepatitis C virus therapy to dateGraham Foster
Queen Mary Hospital, University of London, London, UK
Antivir Ther 13:3-8. 2008....
- Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2bGraham R Foster
Queen Mary University of London, The Liver Unit, Blizard Institute of Cellular and Molecular Science, Barts and the London School of Medicine, The Royal London Hospital, London, UK
Drugs 70:147-65. 2010..Peginterferon plus ribavirin, as the standard of care for patients with chronic hepatitis C, may in the future form the basis of improved treatment regimens that include new, targeted anti-HCV agents to increase SVR rates even further...
- Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infectionsGraham R Foster
Queen Marys University of London, Blizard Institute of Cellular and Molecular Science, London, UK
Gastroenterology 141:881-889.e1. 2011..We evaluated antiviral activity of 2 weeks therapy with telaprevir alone, peginterferon alfa-2a and ribavirin (PR), or all 3 drugs (TPR) in treatment-naïve patients with chronic hepatitis C virus (HCV) genotype 2 or 3 infections...
- Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapyC A Sabin
Hepatobiliary Group, Institute of Cellular and Molecular Science, Queen Mary's School of Medicine and Dentistry, London, United Kingdom
Am J Gastroenterol 100:1509-15. 2005..Asian patients had higher insulin resistance than Caucasians. Insulin resistance is also an important predictor of sustained response to antiviral therapy...
- Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy -- patients' views of early cessation of therapyR D'SOUZA
Department of Gastroenterology, Hepatobiliary Group, Queen Mary s School of Medicine and Dentistry, Barts and The Royal London, London, UK
Aliment Pharmacol Ther 21:43-7. 2005..Patients who do not show a virological response after 12 weeks of therapy have a low probability of sustained virological response and it is therefore recommended that such patients stop treatment...
- Negative correlation between intrahepatic expression of hepatitis C antigens and apoptosis despite high-level expression of Fas and HLA antigensS Caronia
Department of Medicine, Imperial College School of Medicine at St Mary s Hospital, London, UK
J Viral Hepat 11:511-8. 2004....
- Hepatitis C virus infection: quality of life and side effects of treatmentG R Foster
The Liver Unit, Imperial College of Medicine at St Mary s, St Mary s Hospital, London, UK
J Hepatol 31:250-4. 1999....
- Interferon-alpha2a is sufficient for promoting dendritic cell immunogenicityA Tamir
Department of Immunology, Division of Medicine, Faculty of Medicine, Imperial College at Hammersmith Hospital, London, UK
Clin Exp Immunol 142:471-80. 2005..These results clarify some of the in vivo findings obtained with IFN-alpha2a and have direct implications for the design of IFN-alpha-based vaccines for immunotherapy...
- Interferon plus amantadine versus interferon alone in the treatment of naÃ¯ve patients with chronic hepatitis C: a UK multicentre studyS Caronia
Department of Medicine, St Mary's Hospital ICSM, London, UK
J Hepatol 35:512-6. 2001..05) while the sustained response was 18 and 15%, respectively. CONCLUSIONS: Combination therapy with interferon plus amantadine does not lead to a significant increase in sustained response rates when compared to interferon monotherapy...
- Therapeutic options for HCV--management of the infected individualG R Foster
The Liver Centre, Imperial College School of Medicine at St Mary s Hospital, London, UK
Baillieres Best Pract Res Clin Gastroenterol 14:255-64. 2000..New therapies including polyethylene glycol, PEGylated, interferons and combination regimes involving amantadine are currently under evaluation and it is hoped that improved regimes will be developed in the near future...
- Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis CR F C D'Souza
Hepatobiliary Group, Institute of Cellular and Molecular Science, Queen Mary s School of Medicine and Dentistry, London, UK
Aliment Pharmacol Ther 21:519-24. 2005..The increased prevalence of diabetes mellitus has been associated with increased iron deposits in patients with chronic hepatitis C...
- Knowledge of chronic hepatitis C among East London primary care physicians following the Department of Health's educational campaignM J Glynn
Hepatobiliary Group, Barts and The London, Queen Mary's School of Medicine and Dentistry, London, UK
QJM 97:331-6. 2004..Responses among the interviewed GPs were similar. DISCUSSION: Knowledge of hepatitis C among GPs remains poor. Every GP surveyed wished to be better informed. We hope the DH will produce and audit further educational campaigns...
- Hepatitis C virus infection is not associated with a marked increase in the prevalence of ophthalmic morbidityM Leyland
Western Eye Hospital, London, UK
Eye (Lond) 14:889-91. 2000..Chronic infection with the hepatitis C virus has been reported to cause a wide variety of ophthalmic lesions. The incidence and significance of these lesions in an unselected population has not been assessed...
- Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of originG Uddin
Queen Marys University of London, Barts and the London School of Medicine, The Liver Unit, 4 Newark Street, London, UK
J Viral Hepat 17:327-35. 2010..As prevalence varies both by country and region of origin and over time, the prevalence in migrant communities living in western countries cannot be easily predicted from studies in the country of origin...
- The way forward in HCV treatment--finding the right pathMichael P Manns
Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Hannover, Germany
Nat Rev Drug Discov 6:991-1000. 2007..Here we review the specific challenges posed by HCV, and recent developments in the design of vaccines and novel antiviral agents...
- Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis CAnna Hollander
Division of Infectious Diseases, Department of Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
Scand J Gastroenterol 41:577-85. 2006..Early dropouts from therapy have significantly lower HRQOL scores at baseline than adherent patients, and sustained viral responders improve their HRQOL significantly more than non-responders...
- Combination therapy with amantadine and interferon in naÃ¯ve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trialsAlessandra Mangia
Division of Gastroenterology, Ospedale Casa Sollievo Sofferenza, IRCCS, San Giovanni Rotondo 71013, Italy
J Hepatol 40:478-83. 2004..CONCLUSIONS: In chronic hepatitis C, therapy with AMA and INF is effective and may be an alternative to INF and ribavirin in patients who cannot tolerate ribavirin...
- IFN-alpha subtypes differentially affect human T cell motilityGraham R Foster
Hepatobiliary Group, Department of Gastroenterology, Queen Mary's School of Medicine and Dentistry at Barts and The Royal London Hospital, United Kingdom
J Immunol 173:1663-70. 2004..These observations are consistent with the possibility that subtype-specific intracellular signaling pathways are activated by type I IFNs in T lymphocytes...
- Diagnosis and treatment of hepatitis CGraham R Foster
Digestive Disease Research Centre, Royal London Hospital, Turner Street, London E1 1BB, UK
J R Soc Med 97:223-5. 2004
- Advances in the diagnosis and treatment of hepatitis BWilliam Alazawi
The Liver Unit, Barts and the London School of Medicine, London, UK
Curr Opin Infect Dis 21:508-15. 2008..Although the armament of drugs licensed for its treatment grows, it is increasingly apparent that the efficacy of these drugs is dependent upon much more that their pharmacology...
- Interferons at age 50: past, current and future impact on biomedicineErnest C Borden
Taussig Cancer Center, Case Comprehensive Cancer Center, Mellen Center for Multiple Sclerosis, and Lerner Research Institute, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
Nat Rev Drug Discov 6:975-90. 2007..Our goal is to offer a molecular and clinical perspective that will enable IFNs or their TLR agonist inducers to reach their full clinical potential...
- High yield expression, refolding, and characterization of recombinant interferon alpha2/alpha8 hybrids in Escherichia coliDimitris Platis
Imperial College Faculty of Medicine at St. Mary's Hospital, South Wharf Road, London W2 1NY, UK
Protein Expr Purif 31:222-30. 2003....
- Diagnosis and treatment of chronic hepatitis BGraham R Foster
Digestive Disease Research Centre, Queen Mary's School of Medicine and Dentistry, Barts and The London NHS Trust, London, UK
J R Soc Med 97:318-21. 2004
- Different activities of type I interferons on hepatitis B virus core promoter regulated transcriptionEwert Schulte-Frohlinde
Department of Medicine II of the Technical University of Munich, Germany
Cytokine 17:214-20. 2002..The characterization of different effects among type I interferons on HBV-regulatory elements may implicate an IFN-subtype-specific role for the pathogenesis and treatment of HBV-infection...
- Qualitatively distinct patterns of cytokines are released by human dendritic cells in response to different pathogensKaren Scott
Department of Immunology, Division of Medicine, Faculty of Medicine, Imperial College at Hammersmith Hospital, London, United Kingdom
Immunology 116:245-54. 2005..These results support the notion that human dendritic cells are plastic in their response to microbial stimuli and that the nature of the pathogen dictates the response of the dendritic cell...
- Prevalence of hepatitis C-related cirrhosis in elderly Asian patients infected in childhoodMichael J Glynn
Hepatobiliary Group, Department of Adult and Pediatric Gastroenterology, Barts and The London, Queen Mary's School of Medicine and Dentistry, London, United Kingdom
Clin Gastroenterol Hepatol 3:910-7. 2005....
- Dengue virus inhibits alpha interferon signaling by reducing STAT2 expressionMeleri Jones
DDRC, Queen Mary's School of Medicine and Dentistry, Royal Free and University College Medical School, Rowland Hill St, London NW3 2PF, United Kingdom
J Virol 79:5414-20. 2005..Collectively, these data show that dengue virus is capable of subverting the human IFN response by down-regulating STAT2 expression...
- Chronic exposure to Helicobacter pylori impairs dendritic cell function and inhibits Th1 developmentPeter Mitchell
Department of Immunology, Division of Medicine, Faculty of Medicine, Imperial College at Hammersmith Hospital, London, United Kingdom
Infect Immun 75:810-9. 2007..Our results raise the possibility that in chronic H. pylori infection DCs become exhausted after prolonged antigen exposure leading to suboptimal Th1 development. This effect may contribute to persistence of H. pylori infection...
- Activity of hybrid type I interferons in cells lacking Tyk2: a common region of IFN-alpha 8 induces a response, but IFN-alpha2/8 hybrids can behave like IFN-betaDimitris Platis
Imperial College Faculty of Medicine at St. Mary's Hospital, London W2 1NY, England
J Interferon Cytokine Res 23:655-66. 2003..This suggests that this hybrid mimics the interactions of IFN-beta with the receptor and also suggests the existence of a distinct binding site(s) on IFNAR for IFN-beta and some hybrid IFN-alphas...
- IFN-alpha2 induces leukocyte integrin redistribution, increased adhesion, and migrationGeorge Avraamides
Department of Immunology, Division of Medicine, Faculty of Medicine, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Hospital, London W12 0NN, UK
J Interferon Cytokine Res 27:291-303. 2007..These findings have obvious implications for the role of type I IFNs in the development of inflammatory responses leading to the initiation of adaptive immunity...
- Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseasesAmy D Brideau Andersen
Maxygen, Incorporated, 515 Galveston Drive, Redwood City, CA 94063, USA
Proc Natl Acad Sci U S A 104:8269-74. 2007....